JAK2 and myeloproliferative neoplasm: To confirm the prevalence of JAK2 p.V617F mutation in our environment, samples from 300 unselected individuals were assayed for p.V617F, with 1 positive result that corresponded to a patient with a previous diagnosis of myeloproliferative neoplasm.